Product Certification&
    Enterprise Certification

  • Mr.Sinotech
    Tel: 86-371-86181678

  • Mobile:86-371-86181678
  • Tel:86-371-86181678
  • Fax:86-371-86189866
  • URL:http://www.hasinotech.com
  • Province/state:Henan
  • City:Zhengzhou
  • Street:No. 260, Dongming Road,Jinshui District
  • MaxCard:
Home > Products >  Ceritinib CAS: 1032900-25-6

Ceritinib CAS: 1032900-25-6 CAS NO.1032900-25-6

  • FOB Price: USD: 1.00-2.00 /Metric Ton Get Latest Price
  • Min.Order: 5 Metric Ton
  • Payment Terms: L/C,T/T
  • Available Specifications:

    99%(1-5)Metric Ton99%(5-20)Metric Ton

  • Product Details

Keywords

  • Ceritinib
  • LDK 378
  • 1032900-25-6

Quick Details

  • ProName: Ceritinib CAS: 1032900-25-6
  • CasNo: 1032900-25-6
  • Molecular Formula: C28H36ClN5O3S
  • Appearance: White powder
  • Application: Pharmaceutical Raw Intermediates
  • DeliveryTime: Within 2 weeks after order confirmatio...
  • PackAge: 25kg/drum or 20kg/bag
  • Port: Qingdao Port
  • ProductionCapacity: 1000 Metric Ton/Year
  • Purity: 99%
  • Storage: Room Temperature
  • Transportation: By sea or by air
  • LimitNum: 5 Metric Ton
  • CAS: 1032900-25-6
  • Molecular Formula: C28H36ClN5O3S

Superiority

Product name Ceritinib
CAS NO. 1032900-25-6
Synonyms Ceritinib
Category Pharmaceutical Raw Materials,Active Pharmaceutical Ingredients,Bulk Drugs,Fine Chemicals.
Standard purity:>99%
Appearance Ceritinib powder
Shelf life 2 years
Usage

Ceritinib is a drug for the treatment of lung cancer. Ceritinib is an ALK inhibitor.Ceritinib was approved in April 2014 by the Food and Drug Administration for the treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC) following treatment with crizotinib.

 

Details

Product name Ceritinib
CAS NO. 1032900-25-6
Synonyms Ceritinib
Category Pharmaceutical Raw Materials,Active Pharmaceutical Ingredients,Bulk Drugs,Fine Chemicals.
Standard purity:>99%
Appearance Ceritinib powder
Shelf life 2 years
Usage

Ceritinib is a drug for the treatment of lung cancer. Ceritinib is an ALK inhibitor.Ceritinib was approved in April 2014 by the Food and Drug Administration for the treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC) following treatment with crizotinib.

 

 

Other products of this supplier

lookchemhot product CAS New CAS Cas Database Article Data Chemical Catalog